References
- Sung H , FerlayJ , SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer. J. Clin.71(3), 209–249 (2021).
- Bais MV . Targeting oral cancer epigenome via LSD1. Aging (Albany NY).9(12), 2455–2456 (2017).
- Dorna D , PaluszczakJ. The emerging significance of histone lysine demethylases as prognostic markers and therapeutic targets in head and neck cancers. Cells11(6), 1023 (2022).
- Kim D , KimKI , BaekSH. Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases. J. Biomed. Sci.28(1), 41 (2021).
- Bottner J , Ribbat-IdelJ , KlapperLet al. Elevated LSD1 and SNAIL expression indicate poor prognosis in hypopharynx carcinoma. Int. J. Mol. Sci.23(9), 5075 (2022).
- Alsaqer SF , TashkandiMM , KarthaVKet al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget.8(43), 73372–73386 (2017).
- Sheng W , LaFleurMW , NguyenTHet al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell.174(3), 549–563.e19 (2018).
- Yuan C , LiZ , QiBet al. High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer. J. Oral. Pathol. Med.44(2), 159–65 (2015).
- Wang Y , ZhuY , WangQet al. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer. Cancer. Lett.374(1), 12–21 (2016).
- Yang CY , LinCK , TsaoCHet al. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models. Oncotarget.8(20), 33756–33769 (2017).
- Zhang W , ChengJ , DiaoPet al. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Br. J. Cancer.122(4), 528–538 (2020).
- Han Y , XuS , YeWet al. Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade. Cell. Death. Dis.12(11), 993 (2021).
- Wangzhou K , FuW , LiMet al. microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1. Oral. Dis. doi: https://doi.org/10.1111/odi.13944 (2021) ( Online ahead of print).
- Alhousami T , DinyM , AliFet al. Inhibition of LSD1 attenuates oral cancer development and promotes therapeutic efficacy of immune checkpoint blockade and YAP/TAZ inhibition. Mol. Cancer. Res.20(5), 712–721 (2022).
- Fang Y , LiaoG , YuB. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J. Hematol. Oncol.12(1), 129 (2019).